Global Banking & Finance Review® is pleased to announce that Dr. Khaled Harb, Chief Executive Officer of Dar Al Dawa Development and Investment Company, has been named Best Pharmaceutical CEO Middle East 2026 at the Global Banking & Finance Review Awards® 2026.
This award recognises outstanding leadership, strategic vision, innovation, operational excellence, corporate governance, market expansion, stakeholder engagement and long-term value creation within the pharmaceutical industry. The recognition highlights Dr. Harb’s contribution to strengthening Dar Al Dawa’s position as a leading pharmaceutical manufacturer and healthcare solutions provider across the Middle East and international markets.
The Best Pharmaceutical CEO Middle East 2026 award was granted following a comprehensive evaluation process conducted by the Global Banking & Finance Review Awards® research and editorial teams. The assessment considered a range of qualitative and quantitative factors, including visionary leadership, organisational growth, innovation, operational performance, governance standards, market development, talent management, sustainability initiatives and overall contribution to healthcare advancement.
Under Dr. Harb’s leadership, Dar Al Dawa has continued to enhance its capabilities across pharmaceutical development, manufacturing and distribution. The company has remained focused on delivering high-quality healthcare solutions while investing in innovation, operational efficiency and sustainable growth. Through a clear strategic direction and commitment to excellence, the organisation has strengthened its competitive position and expanded its presence across multiple markets.
The pharmaceutical industry operates in an increasingly complex environment shaped by evolving patient needs, regulatory requirements, technological advancements and global healthcare challenges. Effective leadership is therefore critical in ensuring organisations remain innovative, resilient and responsive to changing market dynamics. Dr. Harb has demonstrated these qualities through his focus on long-term growth, operational effectiveness and the continuous development of the organisation’s capabilities.
The Global Banking & Finance Review Awards® programme recognises organisations and individuals that demonstrate excellence, innovation and measurable impact within their respective sectors. Award recipients are selected through an independent review process that evaluates performance against industry-specific benchmarks and criteria. The programme aims to highlight achievements that contribute to organisational success and broader industry development.
Commenting on the achievement, Barnali Pal Sinha, Editor of Global Banking & Finance Review®, said:
“Global Banking & Finance Review® is pleased to congratulate Dr. Khaled Harb on being named Best Pharmaceutical CEO Middle East 2026. Strong leadership continues to play a vital role in driving innovation, operational excellence and sustainable growth within the pharmaceutical sector. Dr. Harb has demonstrated a clear strategic vision and a commitment to organisational development that have contributed significantly to the continued success of Dar Al Dawa. This recognition reflects his leadership and dedication to advancing excellence within both the organisation and the wider healthcare industry.”
As healthcare systems continue to evolve, pharmaceutical companies face increasing demands to balance scientific innovation, regulatory compliance, operational efficiency and commercial performance. Leaders who successfully navigate these challenges help shape the future of healthcare while creating lasting value for patients, stakeholders and communities. The recognition awarded to Dr. Harb acknowledges his contribution in guiding Dar Al Dawa through this evolving landscape while maintaining a strong focus on quality, innovation and sustainable growth.
The Global Banking & Finance Review Awards® are widely recognised for celebrating excellence across a broad range of industries and sectors worldwide. By recognising leaders who consistently deliver strong results and demonstrate forward-thinking leadership, the awards highlight achievements that contribute to both organisational performance and industry progress.
Dr. Harb’s recognition as Best Pharmaceutical CEO Middle East 2026 reflects his commitment to advancing business excellence, fostering innovation and supporting the continued development of the pharmaceutical sector. His leadership has helped position Dar Al Dawa as a trusted provider of pharmaceutical products and healthcare solutions, while reinforcing the company’s dedication to delivering value to customers, partners and stakeholders.
About Dar Al Dawa Development and Investment Company
Dar Al Dawa Development and Investment Company is a pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products and healthcare solutions. Serving markets across the Middle East and internationally, the company focuses on quality, innovation, operational excellence and patient-centred solutions. Through its commitment to research, manufacturing standards and continuous improvement, Dar Al Dawa continues to contribute to the advancement of healthcare and the pharmaceutical industry.
About Global Banking & Finance Review Awards®
The Global Banking & Finance Review Awards® are widely recognized for identifying and celebrating excellence in financial services worldwide. These awards acknowledge outstanding performance, innovation, and leadership across banking, asset management, investment, and fintech sectors, based on stringent evaluation criteria and independent research.
About Global Banking & Finance Review®
Global Banking & Finance Review® is a UK-based financial intelligence and recognition platform established in 2010, providing authoritative news, in-depth analysis, and insights across banking, capital markets, investment, and financial technology. Its industry-leading Digital-First Banking Awards program celebrates institutional and executive excellence worldwide, highlighting achievements in areas such as strategy, risk management, fintech, and leadership. Serving professionals, regulators, and senior market participants across Europe, the Middle East, Asia, Africa, and the Americas, Global Banking & Finance Review® and its awards are recognized for independent, transparent, and data-driven evaluations of performance. Global Banking & Finance Review® is a registered trademark of GBAF Publications Ltd (UK).
